

<b>Active Trials --- Otolaryngology</b>			
<b>Disease</b>	<b>Line</b>	<b>Title</b>	<b>PI</b>
ORA #: 18101103  Sponsor: <b>ARRINEX</b>	Clarifix	Arrinex, Inc. - CT-0004, A Prospective, Multi-Center Registry of Subjects Treated with the ClariFix™ Cryotherapy Device (Pro00027789)	P. Batra
ORA#: 18100505  Sponsor: <b>Optinose</b>	OPN-FLU- CS 3205	OPN-FLU-CS-3205: A 24-Week Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study Evaluating the Efficacy and Safety of Intranasal Administration of 186 and 372 µg of OPN-375 Twice a Day (BID) in Subjects with Chronic Sinusitis with or without the Presence of Nasal Polyps	P. Batra
ORA #: 18061207  Sponsor: <b>INSPIRE</b>	Adhere UAS	Adherence and Outcome of Upper Airway Stimulation (UAS) for OSA International Registry	P. LoSavio
ORA #: 18112705  Sponsor: <b>Optinose</b>	OPN-FLU- NP-3103	OPN-FLU-NP-3103: A 16-Week Randomized, Double-Blind, Placebo Controlled, Parellel-Group, Multicenter Study Evaluating the Efficacy and Safety of OPN-375 186 micrograms Twice a Day (BID) in Adolescents with Bilateral Nasal Polyps Followed by a 12-Week Open-Label Treatment Phase	B. Tajudeen
ORA #: 20042204  Sponsor: <b>Aerin</b>	RHINTRAC	The RhinAer® Procedure for Treatment of CHronic RhInitis - A Prospective, MulticeNter Randomized ConTrolled TRial Comparing RhinAer to Sham Control (RHINTRAC)	B. Tajudeen
ORA #: 19092601  Sponsor: SALVAT	CLOTOT3- 16IA01	A Phase III, Multicenter, Randomized, Double-Blind Clinical Trial to Assess the Efficacy and Safety of Clotrimazole 1% otic solution Compared to Placebo for the Treatment of Fungal Acute Otitis Externa (Otomycosis)	E. Michaelides

<b>Active Trials --- Head and Neck Cancer</b>			
<b>Disease</b>	<b>Line</b>	<b>Title</b>	<b>PI</b>
ORA #: 17121901  Sponsor: <b>MERCK</b>	Newly diagnosed locally advanced Resectable HNSCC	<b>MERCK 689:</b> A Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination With Standard of Care as Adjuvant Therapy for Stage III-IVA Resectable Locoregionally Advanced Head and Neck Squamous Cell Carcinoma (LA HNSCC)	S. Al-Khudari
ORA #: 18122001  Sponsor: <b>NRG</b>	Newly Diagnosed locally advanced Unresectable HNSCC	<b>HN004</b> - Randomized Phase II/III Trial of Radiotherapy with Concurrent MEDI4736 (Durvalumab) vs. Radiotherapy with Concurrent Cetuximab in Patients with Locoregionally Advanced Head and Neck Cancer with a Contraindication to Cisplatin	K. Tatebe
ORA #: 19091703  Sponsor: <b>NRG</b>	Newly Diagnosed Locally Advanced P16+ HNSCC	<b>HN005:</b> A Randomized Phase II/III Trial Of De-Intensified Radiation Therapy For Patients With Early-Stage, P16 Positive, Non-Smoking Associated Oropharyngeal Cancer	M. Jelinek
ORA #: 20070903  Sponsor: <b>NRG</b>	Locally advanced Resectable	<b>HN006</b> – Randomized phase II/III trial of sentinel lymph node biopsy versus elective neck dissection for early-stage oral cavity cancer	M. Bhayani
ORA #: 17030304  Sponsor: <b>UofC</b>	Preventative	<b>PATHWAY:</b> A randomized, double-blind Phase II study of pembrolizumab versus placebo in patients with head and neck cancers at high risk for recurrence or low volume residual disease-the PATHWay Study	M. Fidler
ORA #: 18072004  Sponsor: <b>Rakuten</b>	2 <sup>nd</sup> line- Recurrent/Metas tatic HNSCC	<b>ASP-1929:</b> A Phase 3, Randomized, Double-Arm, Open-Label, Controlled Trial of ASP-1929 Photoimmunotherapy Versus Physician’s Choice Standard of Care for the Treatment of Locoregional, Recurrent Head	M. Fidler

<b>Active Trials --- Head and Neck Cancer</b>			
<b>Disease</b>	<b>Line</b>	<b>Title</b>	<b>PI</b>
ORA #: 18091703  Sponsor: <b>Sensei Therapeutics</b>	2 <sup>nd</sup> line- Recurrent/Metas- tatic HNSCC	<b>SNS-301</b> -An Open-Label, Multi-Center Trial of SNS-301 Added to Pembrolizumab in Previously Treated Patients with ASPH+ Locally Advanced Unresectable or Metastatic/Recurrent Squamous Cell Carcinoma of the Head and Neck	M. Jelinek
ORA #: 18082704  Sponsor: <b>Multivir</b>	1 <sup>st</sup> line- Recurrent/Metas- tatic HNSCC	<b>MULTIVIR</b> – A Phase 2, Multi-Center, Open Label Study to Evaluate Efficacy and Safety of Adenoviral p53 (Ad-p53) in Combination with Nivolumab in Patients with Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC)	K. Stenson
ORA #: 20111903  Sponsor: <b>ECOG</b>	Newly Diagnosed Resectable NPNSCC	<b>EA3136</b> - Phase II randomized trial of neoadjuvant chemotherapy followed by surgery and post-operative radiation versus surgery and post-operative radiation for organ preservation of T3 and T4a nasal and paranasal sinus squamous cell carcinoma (NPNSCC)	M. Jelinek